Vialwirebiotech, curated
November 21, 2026, 7:02 AM
October 30, 2026
- 8:00 AM · Drug Discovery World8:00 AMResearch collab will build AI solutions for accelerated safety screening — Drug Discovery World
- 6:30 AM · BioPharma Dive6:30 AMWith Setara, the team behind Actio opens its second act — BioPharma Dive
- 5:54 AM · Pharmaceutical Technology5:54 AMGlenmark opens Allentown distribution hub in US — Pharmaceutical Technology
- 5:28 AM · Pharmaceutical Technology5:28 AMDren Bio raises $350m for dibotatug clinical development — Pharmaceutical Technology
- 5:00 AM · Drug Discovery World5:00 AMQ3 UK biotech VC heads for record year thanks to megadeals — Drug Discovery World
October 29, 2026
- 10:38 PM · BioPharma Dive10:38 PMAspen raises a $140M IPO in pursuit of a cell therapy for Parkinson’s — BioPharma Dive
- 1:30 PM · Nikkei Asia1:30 PMTakeda bets on blockbuster drug trio to generate $11bn in peak sales — Nikkei Asia
- 12:00 PM · BioWorld12:00 PMLilly’s metabolic sales spark wave of research, investor interest — BioWorld
- 12:00 PM · BioWorld12:00 PMRegulatory: Astrazeneca’s Ultomiris adds accelerated nod in IgAN — BioWorld
- 12:00 PM · BioWorld12:00 PMEarly data good in ESCC, but can Coherus tagmo indications? — BioWorld
- 12:00 PM · BioWorld12:00 PMAustralia’s radiopharma ambitions run into patient-access barriers — BioWorld
- 11:01 AM · Pharmaceutical Technology11:01 AMGaelic Labs: the EU Critical Medicines Act will have a positive impact on supply — Pharmaceutical Technology
- 10:52 AM · BioPharma Dive10:52 AMHHS to allow compounders to make 6 unapproved peptides — BioPharma Dive
- 10:47 AM · Pharmaceutical Technology10:47 AMIDWeek 2026: Abrysvo data in nursing home residents could support re-vaccination — Pharmaceutical Technology
- 9:25 AM · STAT News9:25 AMSTAT+: Vertex kidney disease drug scrutinized for infection risk — STAT News
- 9:00 AM · BioWorld9:00 AMFDA clears IND application for Frontier’s FMC-242 — BioWorld
- 9:00 AM · BioWorld9:00 AMUGX-301 protects the retina through dual complement targeting — BioWorld
- 9:00 AM · BioWorld
- 8:13 AM · Drug Discovery World8:13 AMScionxBio collaborates to develop long-acting xRNA therapeutics — Drug Discovery World
- 7:00 AM · Drug Discovery World7:00 AMRoche licenses Zymeworks’ trispecific T cell engager targeting DLL3 — Drug Discovery World
- 6:30 AM · BioPharma Dive6:30 AMFlagship blends three biotech startups to form Etcelera — BioPharma Dive
- 5:56 AM · Drug Discovery World5:56 AMTILT reports encouraging data at ESMO — Drug Discovery World
- 5:37 AM · Pharmaceutical Technology5:37 AMFormation Bio launches $600m drug development fund — Pharmaceutical Technology
October 28, 2026
- 12:04 PM · Drug Discovery World12:04 PMUK Budget promises £70m for life sciences and lifts VAT on free medicines — Drug Discovery World
- 12:00 PM · BioWorld12:00 PMIdorsia pivots to autism on Quviviq's unexpected phase II benefits — BioWorld
- 12:00 PM · BioWorld12:00 PMGenmab in ‘pole position,’ HNSCC bispecific phase III places strong — BioWorld
- 12:00 PM · BioWorld12:00 PMFDA questions approvability of Sydnexis’ SYD-101 for pediatric myopia — BioWorld
- 11:15 AM · BioPharma Dive11:15 AMFDA unveils guidance for ‘plug and play’ gene therapies — BioPharma Dive
- 10:00 AM · Pharmaceutical Technology10:00 AMIDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease — Pharmaceutical Technology
- 9:42 AM · STAT News9:42 AMSTAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study — STAT News
- 9:27 AM · BioPharma Dive9:27 AMLilly shuffles business structure; Novartis writes off part of Avidity deal — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMALS Association award supports Acurastem’s UNC13A program — BioWorld
- 9:00 AM · BioWorld9:00 AMRumi Therapeutics signs deal with Enthorin for fragile X program — BioWorld